Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegener...

Full description

Saved in:
Bibliographic Details
Main Authors MERGOTT, DUSTIN JAMES, KIELBASA, WILLIAM BRIAN
Format Patent
LanguageChinese
English
Published 01.06.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodengenerative tauopathies, such as Alzheimer's disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy.
Bibliography:Application Number: TW20210126729